A Prospective Pan-European Non-Interventional Study Evaluating Effectiveness Of Lipegfilgrastim In Clinical Practice For The Prophylaxis Of Chemotherapy-Induced Neutropenia In Adult Patients With Different Tumor Types

Trial Profile

A Prospective Pan-European Non-Interventional Study Evaluating Effectiveness Of Lipegfilgrastim In Clinical Practice For The Prophylaxis Of Chemotherapy-Induced Neutropenia In Adult Patients With Different Tumor Types

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 25 Jun 2017

At a glance

  • Drugs Lipegfilgrastim (Primary)
  • Indications Neutropenia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 25 Jun 2017 Interim analysis (n=249, as of Dec 2016) results assesing the effectiveness of lipegfilgrastim in lymphoma patients, presented at the 22nd Congress of the European Haematology Association.
    • 29 Nov 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top